Innovating Biologic Therapies to Combat Fibrosis and Improve Lives
By focusing on innovative peptide therapies like M10, FibroBiologics is setting the stage for a revolution in fibrosis treatment, transforming patient care with cutting-edge science.
Transforming Science into Solutions for Fibrosis
Our mission is to develop life-changing therapies for people suffering from fibrotic diseases, a group of conditions culminating in excessive scarring that currently has limited treatment options.
About Us
At Fibrobiologics, we are committed to transforming the landscape of fibrotic disease treatment by developing breakthrough therapies.
Our Team
Co-founders Richard Silver, M.D., and Galina Bogatkevich, M.D., Ph.D., lead Fibrobiologics alongside a Scientific Advisory Board of experts to drive innovation in fibrotic disease therapies.
Our Science
At the heart of our research is M10, a small peptide that modulates the TGF-β1 pathway—a key driver of fibrosis—by inhibiting downstream inflammatory and fibrotic processes.